ASX:PAA PharmAust (PAA) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free PAA Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.27 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.88%Price TargetN/A Stock AnalysisStock Analysis Get PharmAust alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About PharmAust Stock (ASX:PAA)PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. PAA Stock News HeadlinesApril 10, 2024 | msn.comPharmAust inks approval from Macquarie University for Open-Label MND extension studyMarch 27, 2024 | finance.yahoo.comWe Think PharmAust (ASX:PAA) Can Afford To Drive Business GrowthApril 30, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.March 14, 2024 | msn.comClosing Bell: ASX a little lower after hosting a Big 4 bank midweek spankMarch 14, 2024 | msn.comPharmAust files groundbreaking MND/ALS clinical data with the FDAMarch 13, 2024 | fool.com.auIf you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 nowFebruary 28, 2024 | finance.yahoo.comPharmAust advances monepantel for motor neurone disease towards FDA approvalFebruary 28, 2024 | finanznachrichten.dePharmAust Limited: PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSApril 30, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.February 28, 2024 | msn.comPharmAust’s MPL could offer MND/ALS sufferers up to 56.5 months additional life expectancyFebruary 28, 2024 | finance.yahoo.comPharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSFebruary 21, 2024 | msn.comPharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALSFebruary 16, 2024 | msn.comFDA shows the way for accelerated approval of PharmAust’s monepantel in MNDFebruary 14, 2024 | finance.yahoo.comPharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week aloneFebruary 14, 2024 | msn.comPharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’February 10, 2024 | morningstar.comPlains All American Pipeline LP PAAFebruary 1, 2024 | markets.businessinsider.comPlains All American Pipeline L.P.January 30, 2024 | benzinga.comPlains All American Stock (NASDAQ:PAA) Dividends: History, Yield and DatesJanuary 30, 2024 | msn.comPharmAust gets ethics committee green light for open-label MND extension studyJanuary 28, 2024 | msn.comFDA offers PharmAust clear guidance for orphan drug designation approvalJanuary 23, 2024 | morningstar.comPlains All American Pipeline LPJanuary 16, 2024 | msn.comPharmAust partners with US-based Berry Consultants for Phase 2/3 studyJanuary 1, 2024 | msn.comPharmAust just got a pre-IND meeting with the US FDA to kick off ‘24December 21, 2023 | msn.comUp to $1.8m funding from motor neurone disease foundation could be on the table for PharmAustDecember 20, 2023 | msn.comSanta (and ATO) delivers PharmAust $550k cash boost for ChristmasDecember 12, 2023 | msn.comProminent Perth fundie the main backer in PharmAust’s $3.5m cap raiseDecember 2, 2023 | au.finance.yahoo.comPharmAust Limited (ECQ.F)See More Headlines Receive PAA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmAust and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PAA CUSIPN/A CIKN/A Webwww.pharmaust.com Phone61 8 6161 7412FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,750,000.00 Net Margins-177.28% Pretax MarginN/A Return on Equity-101.98% Return on Assets-31.99% Debt Debt-to-Equity Ratio26.97 Current Ratio4.55 Quick Ratio2.24 Sales & Book Value Annual Sales$3.71 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.50 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares394,330,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Sam Michael Wright A.C.I.S. (Age 46)ACIS, AFin, DipAcc, M.A.I.C.D., MAICD, Finance Director, Company Secretary & Non-Executive Director Comp: $138kMs. Fiona MilnerGeneral Manager of Epichem Pty LtdDr. Michael Thurn Ph.D.CEO & DirectorDr. Gary PittHead of ChemistryDr. James RixsonHead of ProductionKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersSam WrightSold 450,000 sharesTotal: $45,000.00 ($0.10/share)Roger AstonBought 3,649,904 shares on 12/15/2023Total: $18,249.52 ($0.01/share)Neville BassettSold 1,750 sharesTotal: $122.50 ($0.07/share)Sam WrightSold 250,000 sharesTotal: $20,000.00 ($0.08/share)Sam WrightBought 50,000 shares on 5/10/2023Total: $4,100.00 ($0.08/share) This page (ASX:PAA) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarProtect Your Bank Account Before It’s Too LateWeiss RatingsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsJeff Bezos Just Humiliated Elon MuskInvestorPlaceElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmAust Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
